Riskpilot← Back to searchSign inGet full accessCD Pharmaceuticals AB
ABActiveOrg 5568002322Ulls Väg 29 ALeasing of intellectual property and similar products, except copyrighted works · NACE 7740Est. 20102 employees
Revenue 2024
SEK 40,5M
+6% vs 2023
EBITDA margin
14.7%
-21% vs 2023
Equity ratio
49.6%
Financial strength
Net profit 2024
SEK 3,4M
-24% vs 2023
| Revenue | SEK 40,5M | +6% |
| EBITDA | SEK 5,9M | -21% |
| Net profit | SEK 3,4M | -24% |
| Total assets | SEK 35,2M | +6% |
| Equity | SEK 17,4M | +25% |
| Employees | 2 | — |
Legal name
CD Pharmaceuticals AB
Org number
5568002322
Legal form
Aktiebolag
NACE code
7740 · Leasing of intellectual property and similar products, except copyrighted works
Founded
2 februari 2010
Share capital
SEK 100 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska bedriva tillverkning och försäljning av läkemedel och naturläkemedel och därmed förenlig verksamhet.
Address
Ulls Väg 29 A
Phone
+46868436800
Email
info@cdpharmagroup.one
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 6 179 | 15 503 | 36 196 | 38 136 | 40 458 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −1 595 | 4 012 | 10 847 | 7 505 | 5 943 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −895 |
| EBIT | −1 595 | 4 012 | 10 847 | 7 505 | 5 048 |
| Net financials | 940 | −807 | −1 836 | −7 | 328 |
| Profit before tax | 2 | 2 402 | 6 758 | 5 697 | 4 376 |
| Tax | −1 | −497 | −1 394 | −1 194 | −944 |
| Net profit | 1 | 1 905 | 5 364 | 4 503 | 3 432 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 21 907 | 27 807 | 23 185 | 33 027 | 35 154 |
| Equity | 2 234 | 4 139 | 9 503 | 14 006 | 17 438 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 19 409 | 22 600 | 10 362 | 13 900 | 11 596 |
| Total debt | 19 409 | 22 600 | 10 362 | 13 900 | 11 596 |
EBITDA margin
14.7%
This company
15.8%
Market median
-7% vs market
20202024
Equity ratio
49.6%
This company
38.2%
Market median
+30% vs market
20202024
Return on equity
19.7%
This company
18.4%
Market median
+7% vs market
20202024
Net profit margin
8.5%
This company
8.1%
Market median
+5% vs market
20202024
Asset turnover
1.15×
This company
1.12×
Market median
+3% vs market
20202024
Debt / equity
1.02×
This company
0.62×
Market median
-65% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-07-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
BC Chief Auditor | Chief Auditor | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2020 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Rautanes AB
CD Pharmaceuticals AB Board members of CD Pharmaceuticals AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Christer Eriksson | Chief Auditor | 0 companies |
| Paola Salvi | Deputy Board Member | 0 companies |
| Sheetal Devang Parekh | Board of Directors | 0 companies |
| Lars Roland Olsson | Deputy Board Member | 0 companies |